Original articlePancreas, biliary tract, and liver: EditorialSurveillance for Hepatocellular Carcinoma: Can We Focus on the Mission?
References (25)
- et al.
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease
Gastroenterology
(2009) - et al.
Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma
Clin Gastroenterol Hepatol
(2011) - et al.
Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review
J Hepatol
(2010) - et al.
Antiviral therapy for chronic HBV infection and development of hepatocellular carcinoma in a U.S. population
Clin Gastroenterol Hepatol
(2014) - et al.
Racial, social, and clinical determinants of hepatocellular carcinoma surveillance
Am J Med
(2015) - et al.
Suboptimal surveillance for and knowledge of hepatocellular carcinoma among primary care providers
Clin Gastroenterol Hepatol
(2015) - et al.
Improving quality of healthcare for patients with cirrhosis
Gastroenterology
(2014) - et al.
Improved surveillance for hepatocellular carcinoma with a primary care-oriented clinical reminder
Clin Gastroenterol Hepatol
(2015) Hepatocellular carcinoma
N Engl J Med
(2011)- et al.
Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States
Cancer
(2010)
Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group
N Engl J Med
Surveillance for acute viral hepatitis–United States, 2006
MMWR Surveill Summ
Cited by (15)
An automated and mobile magnetoresistive biosensor system for early hepatocellular carcinoma diagnosis
2022, Biosensors and BioelectronicsCitation Excerpt :In addition, HCC has been an escalating problem in the United States where liver cancer rates doubled over the last three decades(Ghouri et al., 2017; Howe et al., 2006; McGlynn et al., 2006; Siegel et al., 2018), largely due to chronic HCV infection, diabetes, and obesity(El-Serag, 2012; Ghouri et al., 2017). Most patients with acute viral infection eventually become chronically infected, progress to fibrosis and cirrhosis, and finally develop HCC(Kanwal et al., 2015; Levrero, 2006; Thorgeirsson and Grisham, 2002, 2002, 2002). About 80% of HCC cases are associated with chronic HBV or HCV infections while the other 20% can be linked to other risk factors, such as heavy alcoholism and nonalcoholic fatty liver disease(Arzumanyan et al., 2013; El-Serag, 2012; Ghouri et al., 2017; Sanyal et al., 2010).
Factors Associated With Delay of Diagnosis of Hepatocellular Carcinoma in Patients With Cirrhosis
2021, Clinical Gastroenterology and HepatologyHepatocellular Carcinoma Screening Is Associated With Increased Survival of Patients With Cirrhosis
2019, Clinical Gastroenterology and HepatologyCitation Excerpt :A prior survey study among primary care providers highlighted a lack of knowledge about screening benefits and society guideline recommendations as one of the most common barriers to HCC screening, underlining the importance of educational efforts among these providers.46 Finally, many patients without screening had unrecognized liver disease and/or cirrhosis, which has been shown to be an important mediating factor for screening underuse.43,47 This may be particularly problematic in the future as HCC epidemiology shifts from viral-mediated to nonalcoholic steatohepatitis, for which laboratory tests are not available to diagnose liver disease and transition to cirrhosis also can be difficult to recognize.
Screening and Early Detection
2019, Abeloff’s Clinical OncologyHepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice
2015, Clinical Gastroenterology and HepatologyCitation Excerpt :Given the low annual incidence rate, the cost effectiveness of HCC surveillance programs in NAFLD or NASH without cirrhosis still requires further evaluation. Although HCC surveillance seems to be an accepted default,90 there is a clear and urgent need for interventions to address its shortcomings. Studies have suggested that interventions should be aimed at the provider or system level.
Chronic hepatitis B: A wave of new therapies on the horizon
2015, Antiviral ResearchCitation Excerpt :More than 350 million people are chronically infected with hepatitis B virus (HBV), with some 600,000 deaths per year attributed to the virus (El-Serag and Rudolph, 2007; Kanwal et al., 2015).
Conflicts of interest The authors disclose no conflicts.